# ClinicalTrials.gov record NCT04167163

> PeptideScanner retained ClinicalTrials.gov record NCT04167163 at 2026-07-30T16:19:03.051Z. Its registry update date was 2026-06-05, and PeptideScanner's reviewed identity mapping was abaloparatide.

- Evidence object: `story:clinicaltrials-gov-nct04167163-abaloparatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-06-05
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-08
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct04167163-abaloparatide/
- JSON record: https://peptidescanner.com/evidence/v1/objects/clinicaltrials-gov-nct04167163-abaloparatide-v1.json
- Content SHA-256: `d2b1ac2e14e661d314a04cbc30a1c3bf7f18d3b8a2e329406394706c7d290cb4`

## Claims and source pins

### Headline

ClinicalTrials.gov record NCT04167163 ([`ctg-observation-nct04167163-2026-06-05-4701baaec736`](#source-ctg-observation-nct04167163-2026-06-05-4701baaec736))

### Summary

PeptideScanner retained ClinicalTrials.gov record NCT04167163 at 2026-07-30T16:19:03.051Z. Its registry update date was 2026-06-05, and PeptideScanner's reviewed identity mapping was abaloparatide. ([`ctg-observation-nct04167163-2026-06-05-4701baaec736`](#source-ctg-observation-nct04167163-2026-06-05-4701baaec736))

### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT04167163 at 2026-07-30T16:19:03.051Z. Its registry update date was 2026-06-05, and PeptideScanner's reviewed identity mapping was abaloparatide. ([`ctg-observation-nct04167163-2026-06-05-4701baaec736`](#source-ctg-observation-nct04167163-2026-06-05-4701baaec736))

### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct04167163-2026-06-05-4701baaec736`](#source-ctg-observation-nct04167163-2026-06-05-4701baaec736))

## Sources

<a id="source-ctg-observation-nct04167163-2026-06-05-4701baaec736"></a>
- **ClinicalTrials.gov record NCT04167163 · retained source version 2026-06-05:4701baaec73635fa789d2ef70899f44d5f0df314cb6175e53f9a5e9379badc86** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT04167163) (`ctg-observation-nct04167163-2026-06-05-4701baaec736`)

## Correction lineage

No correction is recorded for this version.

## Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

## Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT04167163." Version 1, published 2026-08-08. https://peptidescanner.com/evidence/v1/objects/clinicaltrials-gov-nct04167163-abaloparatide-v1.json SHA-256: d2b1ac2e14e661d314a04cbc30a1c3bf7f18d3b8a2e329406394706c7d290cb4.